Warning: Undefined variable $insensitive in
/home/u792129758/domains/sciencefather.com/public_html/academicawards/wp-content/plugins/internal-link-building-plugin/internal_link_building.php on line
201
Warning: Undefined variable $insensitive in
/home/u792129758/domains/sciencefather.com/public_html/academicawards/wp-content/plugins/internal-link-building-plugin/internal_link_building.php on line
202
👨⚕️ Dr. Philippe Collery is a distinguished figure in the medical field, embarking on his journey in 1967 as an Intern at the Universitary Hospital of Reims, where he honed his skills until 1978. Over the years, he earned his stripes, becoming a Medical Doctor in 1976, a Specialist in Internal Medicine in 1980, and an Oncologist in 1987. His dedication continued as a Medical Assistant from 1978 to 1982 and later as a Medical Physician at the Universitary Hospital of Reims from 1982 to 2000.
From 2000 to 2013, Dr. Collery served as an Oncologist at the Polyclinique Maymard in Corsica, France, contributing significantly to cancer care. Currently, he wears the hat of the Manager at the Society for Coordination for Therapeutic Researches since 2005, spearheading breakthroughs in pharmaceuticals. Notably, he is the owner of the patent on “Rhenium complexes and their pharmaceutical use,” securing European and US patents in 2015, followed by Japanese and Canadian patents in 2017.
Dr. Collery’s influence extends beyond clinical practice; he organized the 1st International Symposium on Metal Ions in Biology and Medicine in Reims in 1990, garnering official sponsorship from the Food and Drug Administration (FDA). As a co-editor of 11 proceeding books on Metal Ions in Biology and Medicine and an author of over 100 research articles, he remains at the forefront of scientific discourse. Dr. Collery is a member of the International Scientific Committee for various Anticancer Research conferences, actively contributing to the field. His role as a coordinator for clinical trials on gallium chloride underscores his commitment to advancing oncological research. 🌐🔬👨⚕️
Professional Profiles:
Scopus
Orcid
Publication Top Note:
- Plasma Rhenium and Selenium Concentrations After Repeated Daily Oral Administration of Rhenium(I)-diselenoether in 4T1 Breast Tumor-bearing Mice
- Author: Collery, P., Michalke, B., Lucio, M., … Schmid-Antomarchi, H., Schmid-Alliana, A.
- Year: 2023
- Journal: Anticancer Research
- Volume: 43(3)
- Pages: 1017–1023
- Citations: 1 📚🔬
- Remarkable Effects of a Rhenium(I)-diselenoether Drug on the Production of Cathepsins B and S by Macrophages and their Polarizations
- Author: Collery, P., Desmaële, D., Harikrishnan, A., Veena, V.
- Year: 2023
- Journal: Current Pharmaceutical Design
- Volume: 29(30)
- Pages: 2396–2407
- Citations: 0 📚⚛️
- Quantification of drug loading in polymeric nanoparticles using AFM-IR technique: a novel method to map and evaluate drug distribution in drug nanocarriers
- Author: Ural, M.S., Dartois, E., Mathurin, J., … Deniset-Besseau, A., Gref, R.
- Year: 2022
- Journal: Analyst
- Volume: 147(23)
- Pages: 5564–5578
- Citations: 2 📚🔬
- Relationship between the oxidative status and the tumor growth in transplanted triple-negative 4T1 breast tumor mice after oral administration of rhenium(I)-diselenoether
- Author: Collery, P., Lagadec, P., Krossa, I., … Schmid-Antomarchi, H., Schmid-Alliana, A.
- Year: 2022
- Journal: Journal of Trace Elements in Medicine and Biology
- Volume: 71
- Pages: 126931
- Citations: 3 📚🧪
- Effects of rhenium(I)-diselenoether and of its diselenide ligand on the production of cathepsins B and S by MDA-MB231 breast malignant cells
- Author: Collery, P., Veena, V., Desmaële, D., Harikrishnan, A., Lakshmi, B.
- Year: 2021
- Journal: Anticancer Research
- Volume: 41(12)
- Pages: 5997–6001
- Citations: 4 📚⚛️
- A new model applied for evaluating a rhenium-diselenium drug: Breast cancer cells stimulated by cytokines induced from polynuclear cells by LPS
- Author: Veena, V., Harikrishnan, A., Lakshmi, B., … Desmaele, D., Collery, P.
- Year: 2020
- Journal: Anticancer Research
- Volume: 40(4)
- Pages: 1915–1920
- Citations: 11 📚🧬
- The rhenium(I)-diselenoether anticancer drug targets ROS, TGF-β1, VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers
- Author: Collery, P., Veena, V., Harikrishnan, A., Desmaele, D.
- Year: 2019
- Journal: Investigational New Drugs
- Volume: 37(5)
- Pages: 973–983
- Citations: 31 📚⚛️
- Design of rhenium compounds in targeted anticancer therapeutics
- Author: Collery, P., Desmaele, D., Vijaykumar, V.
- Year: 2019
- Journal: Current Pharmaceutical Design
- Volume: 25(31)
- Pages: 3306–3322
- Citations: 45 📚⚛️
- Strategies for the development of selenium-based anticancer drugs
- Author: Collery, P.
- Year: 2018
- Journal: Journal of Trace Elements in Medicine and Biology
- Volume: 50
- Pages: 498–507
- Citations: 67 📚🔍